(To see other currencies, click on price)
MORE ABOUT THIS BOOK
Main description:
A panel of leading academic and pharmaceutical investigators takes stock of the remarkable work that has been accomplished to date with proteasome inhibitors in cancer, and examines emerging therapeutic possibilities. The topics range from a discussion of the chemistry and cell biology of the proteasome and the rationale for proteasome inhibitors in cancer to a review of current clinical trials underway. The discussion of rationales for testing proteasome inhibitors in cancer models covers the role of the proteasome in NF-kB activation, the combining of conventional chemotherapy and radiation with proteasome inhibition, notably PS-341, new proteasome methods of inhibiting viral maturation, and the role of protesome inhibition in the treatment of AIDS. The authors also document the development of bortezomib (Velcade (TM)) in Phase I clinical trials and in a multicentered Phase II clinical trials in patients with relapsed and refractory myeloma.
Contents:
I. Cancer Drug Development
Cancer Drug Development: Challenges in a Competitive Market
Barry Greene and Michael Kauffman
II. Chemistry and Cell Biology of the Proteasome
Introduction to the Proteasome and Its Inhibitors: Biochemistry and Cell Biology
Alfred L. Goldberg
Structures of the Yeast Proteasome Core Particle in Complex with Inhibitors
Michael Groll and Robert Huber
Natural Product and Synthetic Proteasome Inhibitors
Kyung Bo Kim and Craig M. Crews
Other Proteasome Inhibitors
Carlos Garcia-Echeverria
The Proteasome in Cell-Cycle Regulation
Julian Adams
Proteasome Inhibition and Apoptosis
Simon A. Williams and David J. McConkey
The Proteasome and the COMPARE Algorithm
Susan L. Holbeck and Edward A. Sausville
III. Rationale for Proteasome Inhibitors in Cancer
The Proteasome in Cancer Biology and Therapy
Frank Pajonk and William H. McBride
Radiosensitization and Proteasome Inhibition
Carter Van Waes, John B. Sunwoo, William DeGraff, and James B. Mitchell
Proteasome-Dependent Regulation of NF-kB Activation: Molecular Targeting of Chemotherapy Resistance
James C. Cusack, Jr.
Bortezomib with Taxanes
Leonard Liebes, Bruce Ng, Yi-He Ling, and Roman Perez-Soler
Proteasome Inhibitor Therapy in a Brain Tumor Model
Jeffrey J. Olson, Geoffrey Bowers, and Zhaobin Zhang
Anthracyclines and Bortezomib
Robert Z. Orlowski
TNF-Related Apoptosis-Inducing Ligand (TRAIL): Combination with Proteasome Inhibition For Anticancer Therapy?
Thomas J. Sayers
Rationale for Combining the Proteasome Inhibitor Bortezomib with Cisplatin
Edward G. Mimnaugh and Leonard M. Neckers
The Effects of the HIV-1 Protease Inhibitor Ritonavir on Proteasome Activity and Antigen Presentation
Marcus Groettrup, Rita deGiuli, and Gunter Schmidtke
Function(s) of the Ubiquitin-Proteasome System in Retrovirus Budding
Ulrich Schubert
IV. Clinical Trials
Preclinical Development of Bortezomib (VELCADE (TM)): Rationale for Clinical Studies
Julian Adams, Peter J. Elliott, and Page Bouchard
Phase I Trials: Bortezomib Alone and in Combination With Standard Chemotherapies
Dixie-Lee W. Esseltine and David P. Schenkein
Clinical Molecular Diagnostics for Proteasome Inhibitors in Cancer Therapy
Jeffrey S. Ross, Gerald P. Linette, Geoffrey S. Ginsburg, William Trepicchio, Oscar Kashala, Rebecca Mosher, Jeffrey Brown, George Mulligan, Jim Deeds, and James Stec
Phase II Trials of Bortezomib for the Treatment of Multiple Myeloma
Kenneth C. Anderson
Index
PRODUCT DETAILS
Publisher: Springer (Humana Press Inc.)
Publication date: November, 2010
Pages: 328
Weight: 694g
Availability: Available
Subcategories: Oncology, Pharmacology
From the same series
